» Articles » PMID: 19390908

Undifferentiated Connective Tissue Disease: a Seven-center Cross-sectional Study of 184 Patients

Overview
Journal Clin Rheumatol
Publisher Springer
Specialty Rheumatology
Date 2009 Apr 25
PMID 19390908
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to characterize the clinical and serological features of a large cohort of patients with antinuclear antibody (ANA) positive undifferentiated connective tissue disease (UCTD). Consecutive patients with UCTD, followed up at the Rheumatology Clinic of the participating centers, were included. Data from these patients were obtained by clinical evaluation and chart review. All patients were diagnosed as having UCTD on basis of the following criteria: positive ANA plus at least one clinical feature of connective tissue disease, but not fulfilling classification criteria for any differentiated connective tissue disease. One hundred eighty-four patients were studied (female patients-94.5%; mean age at time of evaluation-47 years). The most prevalent manifestations were arthralgia (66%), arthritis (32%), Raynaud's phenomenon (30%), sicca symptoms (30%), and leukopenia (19%). The prevalence of ANA was 100%, anti-SSA 20%, anti-dsDNA 14%, and anti-SSB 7%. Patients with anti-dsDNA/anti-Sm, anticentromere/anti-Scl70, or anti-SSA/anti-SSB antibodies more frequently presented a set of manifestations close to systemic lupus erythematosus (SLE), systemic sclerosis, or Sjögren syndrome, respectively. We analyze a large cohort of UCTD. Seventy-two percent of these UCTD patients present lupus-, scleroderma-, or Sjögren-like features but do not fulfill classification criteria and mostly present a mild disease.

Citing Articles

A rare case of non-infectious mitral valve vegetation in a patient with undifferentiated connective tissue disease.

Xie F, Chai J, Chai L, Wang J, Li Z, Huang B Quant Imaging Med Surg. 2024; 14(7):5263-5267.

PMID: 39022228 PMC: 11250331. DOI: 10.21037/qims-23-1851.


Undifferentiated Connective Tissue Disease in Pregnancy: A Topic Yet to be Explored.

Serena C, Clemenza S, Simeone S, Zullino S, Ottanelli S, Rambaldi M Front Pharmacol. 2022; 13:820760.

PMID: 35126164 PMC: 8811283. DOI: 10.3389/fphar.2022.820760.


Differentiating between UCTD and early-stage SLE: from definitions to clinical approach.

Sciascia S, Roccatello D, Radin M, Parodis I, Yazdany J, Pons-Estel G Nat Rev Rheumatol. 2021; 18(1):9-21.

PMID: 34764455 DOI: 10.1038/s41584-021-00710-2.


Interstitial Lung Disease Associated with Connective Tissue Diseases.

Peredo R, Mehta V, Beegle S Adv Exp Med Biol. 2021; 1304:73-94.

PMID: 34019264 DOI: 10.1007/978-3-030-68748-9_5.


A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens....

Yang S, Ni R, Lu Y, Wang S, Xie F, Zhang C Trials. 2020; 21(1):771.

PMID: 32907619 PMC: 7488113. DOI: 10.1186/s13063-020-04716-1.


References
1.
Petri M . Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am. 2005; 31(2):245-54, vi. DOI: 10.1016/j.rdc.2005.01.009. View

2.
Bodolay E, Csiki Z, Szekanecz Z, Ben T, Kiss E, Zeher M . Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003; 21(3):313-20. View

3.
LeRoy E, Medsger Jr T . Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001; 28(7):1573-6. View

4.
Dijkstra S, Nieuwenhuys E, Swaak A . The prognosis and outcome of patients referred to an outpatient clinic for rheumatic diseases characterized by the presence of antinuclear antibodies (ANA). Scand J Rheumatol. 1999; 28(1):33-7. DOI: 10.1080/03009749950155751. View

5.
Mosca M, Neri R, Bombardieri S . Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999; 17(5):615-20. View